Skip to content

Enhanced Recovery Open Versus Laparoscopic Donor Nephrectomy

Mansoura Enhanced Recovery Open Versus Laparoscopic Donor Nephrectomy (MEnROL): A Randomized Controlled Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02699489
Acronym
MEnROL
Enrollment
224
Registered
2016-03-04
Start date
2013-01-31
Completion date
2015-11-30
Last updated
2016-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Transplant Donor of Left Kidney

Brief summary

A phase III randomized trial conducted to compare recovery outcomes between laparoscopic and open donor nephrectomy within a specified enhanced recovery protocol

Detailed description

The MEnROL trial is a phase III randomized controlled trial of Open versus Laparoscopic donor nephrectomy within a standardized enhanced recovery program. Eligible donors were randomized in a 1:1 ratio. Laparoscopic procedures are performed by a single surgeon (AMM) while Open donor nephrectomies (ODN) were performed by an experienced team that included the laparoscopic surgeon. ODN were performed via a supracostal incision above the 11th rib and an extra-pleural extra-peritoneal approach was adopted. Laparoscopic donor nephrectomy (LDN) was performed via a standard 4-port distribution. Control of the hilar vessels was performed using extra-large Hem-o-Lok clips (Weck- Covidien, Research Triangle Park, NC) and graft extraction was performed via a pre-prepared Pfannenstiel incision. Donors are enrolled in our enhanced recovery program for donor nephrectomy. The program was compliant with the Enhanced Recovery After Surgery Group (ERAS) guidelines. All donors receive epidural analgesia and are maintained on non-narcotic postoperative analgesics. Criteria for hospital discharge include ambulation, adequate pain control with oral analgesics, and sustained intake of solid food.

Interventions

Laparoscopic donor nephrectomy performed via a standard 4-port distribution. Control of the hilar vessels is performed using extra-large Hem-o-Lok clips (Weck- Covidien, Research Triangle Park, NC) and graft extraction is performed via a pre-prepared Pfannenstiel incision

Open donor nephrectomy performed via a supracostal incision above the 11th rib and an extra-pleural extra-peritoneal approach was adopted

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

1. Donor aged 18 years or more. 2. Donors who have the ability to understand information and materials provided. 3. Donors who didn't express a preference for either open or laparoscopic surgery. 4. Donors who are fit for both open and laparoscopic intervention 5. Donors in whom evaluation revealed left kidney with single renal artery suitable for donation. 6. Donors able to give signed written informed consent.

Exclusion criteria

1. Donors who had a preference for either open or laparoscopic surgery. 2. Donors in whom the right kidney was chosen for donation. 3. Donors with double renal arteries in kidneys chosen for donation. 4. Donors who didn't sign consent.

Design outcomes

Primary

MeasureTime frame
Donor recovery as evaluated by the physical fatigue domain of the Multidimensional Fatigue Inventory 20 (MFI-20),6 weeks

Secondary

MeasureTime frameDescription
Length of Hospital stayup to 2 weeksLength of hospital stay in days
Ischemia timesup to 1 dayWarm and Cold ischemia times in minutes
Duration of the procedureup to 24 hoursDuration of the procedure in minutes
Short Form-36 (SF-36) health survey6 weeksScores of Short Form-36 questionnaire
One year graft loss1 yearIncidence of one year graft loss in both groups
Recipient complications90 daysIncidence of recipient complications in both groups
Peri-operative complications90 daysIncidence of peri-operative complications in both groups

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026